Finch Therapeutics Group, Inc., (FNCH) News
Filter FNCH News Items
FNCH News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest FNCH News From Around the Web
Below are the latest news stories about FINCH THERAPEUTICS GROUP INC that investors may wish to consider to help them evaluate FNCH as an investment opportunity.
Billionaire Seth Klarman’s Biotech Stock PicksIn this article, we discuss billionaire Seth Klarman’s biotech stock picks. To skip the detailed analysis of the biotech industry, Seth Klarman’s investment philosophy, and Baupost Group’s performance and Q3 bets, go directly to Billionaire Seth Klarman’s Top 4 Biotech Stock Picks. Biotechnology is the technology segment that utilizes cellular and biomolecular processes for the […] |
Finch Announces Reverse Stock Split of Common StockBOSTON, June 09, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today announced it will effect a one-for-30 reverse stock split of its issued and outstanding common stock. Finch stockholders approved an amendment to its Amended and Restated Certificate of Incorporation to effect the reverse stock split at Finch’s Annual Meeting |
The Petri Dish: Laronde CEO exits after 6 months; Enanta seeks Covid pill partnerFinch Therapeutics forges a path forward, Insulet shakes up its C-suite, plus other biotech news in the Petri Dish. |
Finch Therapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdatesSOMERVILLE, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today reported first quarter 2023 financial results and provided business updates. “Finch has continued to execute on its strategy to advance its novel microbiome technology through partnerships and collaborations, highlighted by the recent investigator-s |
Finch Therapeutics Announces Executive Leadership TransitionsMatthew P. Blischak, an experienced life sciences executive and intellectual property counsel, appointed as Chief Executive Officer effective May 16, 2023; Mark Smith, PhD, to complete his time as CEO effective May 15 Lance Thibault, Managing Director of Danforth Advisors, to serve as Chief Financial Officer effective May 16, 2023; Marc Blaustein to complete his time as Chief Operating Officer and principal financial officer effective May 15 SOMERVILLE, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- |
Finch Therapeutics Announces Clinical Collaboration in Ulcerative Colitis with Brigham and Women’s Hospital and Updates to University of Minnesota License AgreementSOMERVILLE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today announced that it has entered into a clinical trial agreement with Brigham and Women’s Hospital for the evaluation of CP101, a Complete Consortia microbiome therapeutic, in ulcerative colitis. The Company also announced updates to its license agre |
Finch Therapeutics Group Full Year 2022 Earnings: Misses ExpectationsFinch Therapeutics Group ( NASDAQ:FNCH ) Full Year 2022 Results Key Financial Results Net loss: US$114.6m (loss widened... |
Finch Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdatesSOMERVILLE, Mass., March 23, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today reported fourth quarter and full year 2022 financial results and provided business updates. “We believe that Finch has made significant progress towards restructuring the business to maximize value for shareholders through our robust intellectual |
Microbiome startup cuts 95% of remaining staff in 3rd layoff in 9 monthsA Somerville microbiome startup appears to be in its final days after announcing plans to cut 95% of its workforce. |
Finch Therapeutics Halts Work On Its Only Clinical Stage Asset, Cuts 95% Of WorkforceFinch Therapeutics Group Inc (NASDAQ: FNCH) will discontinue the PRISM4 Phase 3 trial of CP101 in recurrent C. difficile infection (CDI) and focus on realizing the value of its intellectual property estate and other assets. The decision follows an assessment of several factors, including the company's outlook for securing additional capital or partnerships to help fund the CP101 program, slower-than-anticipated enrollment in the PRISM4 trial, and broader sector trends. Finch is reducing its work |